A Phase III, Randomized, Double Blind, Non-inferiority, Comparative Study of the New Transdermal Patch Dosage Form Containing Loxoprofen Sodium (100 mg) and Loxonin (60 mg Tablet) for the Treatment of Acute Traumatic Injuries

Trial Profile

A Phase III, Randomized, Double Blind, Non-inferiority, Comparative Study of the New Transdermal Patch Dosage Form Containing Loxoprofen Sodium (100 mg) and Loxonin (60 mg Tablet) for the Treatment of Acute Traumatic Injuries

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Loxoprofen (Primary) ; Loxoprofen
  • Indications Pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Daiichi Sankyo Brasil
  • Most Recent Events

    • 13 Feb 2017 Status changed from recruiting to completed.
    • 01 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top